Surveillance for mid- and long-term anti-retroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors following lopinavir/ritonavir, in Europe and Thailand.
Methods
Cohorts contributed individual patient data on adverse events (AE) in those aged <18 years taking DRV and ATV, respectively, to 02/2014. Rates of Division of AIDS (DAIDS) grade ≥3 laboratory AEs were calculated.
Results
Of 431 patients on DRV and 372 on ATV, 317 (74%) and 301 (81%), respectively, had weight and dose data available, of whom 56 (18%) and 33 (9%) took the drugs at a non-approved age or dose. Median age at DRV and ATV start was 14.8 years (IQR 12.8–16.1) and 13.5 years (11.4–15.2); 43% and 26% had received ≥8 ART drugs previously. Overall rates of grade ≥3 AEs for absolute neutrophils, total cholesterol, triglycerides, pancreatic amylase, lipase and alanine aminotransferase (ALT) were ≤3/100 person-years (PY) on approved doses of both drugs, but 66/100 PY (95% CI 52, 84) for bilirubin after <12 months on ATV declining to 32/100 PY (95% CI 23, 44) after >24 months. Five serious drug-related clinical AEs were reported in four patients on ATV (one discontinued) and three in three patients on DRV (all discontinued), and did not substantially differ in those on approved compared to non-approved doses. Proportions on the drugs at last follow-up were 89% (383/431) for DRV and 81% (301/372) for ATV (including 73/92 with grade ≥3 hyperbilirubinaemia).
Conclusions
AEs were few in number and comparable for the two drugs, with the exception of high rates of hyperbilirubinaemia for ATV; few patients discontinued due to toxicity.
References
1.
Janssen–Cilag Ltd. Summary of product characteristics: Prezista 75 mg, 150 mg, and 600 mg film-coated tablets. (Accessed 2 February 2015.) Available from http://www.medicines.org.uk/emc/medicine/27325.
2.
Bristol–Myers Squibb Pharmaceutical Limited. Summary of product characteristics: Reyataz 150 mg, 200 mg and 300 mg hard capsules. (Accessed 2 February 2015.) Available from http://www.medicines.org.uk/emc/medicine/14145.
3.
BamfordA., TurkovaA., LyallH.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimising health in preparation for adult life.HIV Med2015; doi: 10.1111/hiv.12217.
4.
Lyall H, KONCERT Trial Team.Final results of KONCERT: a randomized noninferiority trial of QD vs BD LPV/r dosing in children.Conference on Retroviruses and Opportunistic Infections (CROI). 3–6 March 2014, Boston, MA, USA. Abstract 74LB.
5.
FlynnP., KomarS., BlancheS.Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naive, HIV-1-infected adolescents: results from a Phase 2 open-label trial (DIONE).Pediatr Infect Dis J2014; 33: 940–945.
6.
BlancheS., BolognaR., CahnP.Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.AIDS2009; 23: 2005–2013.
7.
ViolariA., BolognaR., KumarasamyN.Safety and efficacy of darunavir/ritonavir in treatment-experienced paediatric patients aged 3 to <6 years: week 48 analysis of the ARIEL trial. (Accessed 2 February 2015.) Available from http://regist2.virology-education.com/2014/8INTEREST/51_violari.pdf.
8.
Division of AIDS.Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; clarification August 2009. Bethesda, MD: National Institutes of Health2009.
9.
AchenbachC.J., DarinK.M., MurphyR.L., KatlamaC.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Future Virol2011; 6: 157–177.
10.
RutsteinR.M., SamsonP., FentonT.Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.Pediatr Infect Dis J2015; 34: 162–167.
11.
TortiC., LapadulaG., AntinoriA.Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.Infection2009; 37: 244–249.
12.
HavlirD.V., O'MarroS.D.Atazanavir: new option for treatment of HIV infection.Clin Infect Dis2004; 38: 1599–1604.
13.
MöbiusU., Lubach-RuitmanM., Castro-FrenzelB.Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.J Acquir Immune Defic Syndr2005; 39: 174–180.
14.
JuddA., DuongT., GalliL.Post-licensing safety of fosamprenavir in HIV-infected children in Europe.Pharmacoepidemiol Drug Saf2014; 23: 321–325.
15.
SharlandM., BlancheS., CastelliG., RamosJ., GibbD.M.PENTA guidelines for the use of antiretroviral therapy, 2004.HIV Med2004; 5Suppl 2: 61–86.
16.
TassiopoulosK., WilliamsP.L., SeageG.R.IIIAssociation of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.J Acquir Immune Defic Syndr2008; 47: 607–614.
17.
JacobsonD.L., WilliamsP., TassiopoulosK., MelvinA., HazraR., FarleyJ.Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.J Acquir Immune Defic Syndr2011; 57: 413–420.
18.
RhoadsM.P., LaniganJ., SmithC.J., LyallE.G.Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV.J Acquir Immune Defic Syndr2011; 57: 404–412.
19.
OfotokunI., NaL.H., LandovitzR.J.Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.Clin Infect Dis2015; 60: 1842–1851.
20.
Soler-PalacínP., MelendoS., Noguera-JulianA.Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.AIDS2011; 25: 171–176.
